dc.contributor.author |
Lagerstedt, Linnéa |
dc.contributor.author |
Egea Guerrero, Juan José |
dc.contributor.author |
Bustamante, Alejandro |
dc.contributor.author |
Montaner, Joan |
dc.contributor.author |
Rodríguez Rodríguez, Ana |
dc.contributor.author |
El Rahal, Amir |
dc.contributor.author |
Turck, Natacha |
dc.contributor.author |
Quintana, Manuel |
dc.contributor.author |
García Armengol, Roser |
dc.contributor.author |
Prica, Carmen Melinda |
dc.contributor.author |
Andereggen, Elisabeth |
dc.contributor.author |
Rinaldi, Lara |
dc.contributor.author |
Sarrafzadeh, Asita |
dc.contributor.author |
Schaller, Karl |
dc.contributor.author |
Sanchez, Jean-Charles |
dc.date |
2017 |
dc.identifier |
https://ddd.uab.cat/record/196403 |
dc.identifier |
urn:10.1371/journal.pone.0175572 |
dc.identifier |
urn:oai:ddd.uab.cat:196403 |
dc.identifier |
urn:pmid:28419114 |
dc.identifier |
urn:scopus_id:85017620080 |
dc.identifier |
urn:wos_id:000399875200027 |
dc.identifier |
urn:altmetric_id:19144140 |
dc.identifier |
urn:oai:egreta.uab.cat:publications/9371d2ed-cb1b-4f10-a712-34fd76c85884 |
dc.identifier |
urn:pmc-uid:5395174 |
dc.identifier |
urn:pmcid:PMC5395174 |
dc.identifier |
urn:oai:pubmedcentral.nih.gov:5395174 |
dc.format |
application/pdf |
dc.language |
eng |
dc.publisher |
|
dc.relation |
PloS one ; Vol. 12 Núm. 4 (2017), p. 1-11 |
dc.rights |
open access |
dc.rights |
Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original. |
dc.rights |
https://creativecommons.org/licenses/by/4.0/ |
dc.title |
H-FABP: A new biomarker to differentiate between CT-positive and CT-negative patients with mild traumatic brain injury |
dc.type |
Article |
dc.description.abstract |
The majority of patients with mild traumatic brain injury (mTBI) will have normal Glasgow coma scale (GCS) of 15. Furthermore, only 5%±8% of them will be CT-positive for an mTBI. Having a useful biomarker would help clinicians evaluate a patient's risk of developing intracranial lesions. The S100B protein is currently the most studied and promising biomarker for this purpose. Heart fatty-acid binding protein (H-FABP) has been highlighted in brain injury models and investigated as a biomarker for stroke and severe TBI, for example. Here, we evaluate the performances of S100B and H-FABP for differentiating between CT-positive and CT-negative patients. A total of 261 patients with a GCS score of 15 and at least one clinical symptom of mTBI were recruited at three different European sites. Blood samples from 172 of them were collected 6 h after trauma. Patients underwent a CT scan and were dichotomised into CT-positive and CT-negative groups for statistical analyses. HFABP and S100B levels were measured using commercial kits, and their capacities to detect all CT-positive scans were evaluated, with sensitivity set to 100%. For patients recruited 6 h after trauma, the CT-positive group demonstrated significantly higher levels of both H-FABP (p = 0.004) and S100B (p = 0.003) than the CT-negative group. At 100% sensitivity, specificity reached 6% (95% CI 2.8±10.7) for S100B and 29% (95% CI 21.4± 37.1) for H-FABP. Similar results were obtained when including all the patients recruited, i.e. hospital arrival within 24 h of trauma onset. H-FABP out-performed S100B and thus seems to be an interesting protein for detecting all CT-positive mTBI patients with a GCS score of 15 and at least one clinical symptom. |